Dec 1, 2021 · IMM-1-104 drives deep, cyclic inhibition of the MAPK pathway (improving tolerability) while resisting pathway bypass mechanisms (improving activity). Our collective data suggest that RAS and RAF mutant tumor cells are not able to tolerate periods of deep but cyclic MAPK pathway inhibition.

imm-1-104 Our lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers.

1 day ago · The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer.

IMM-1-104 Phase 1: Summary of Treatment-Related Adverse Events • As of February 20, 2024, EDC snapshot:No IMM-1-104 treatment-related adverse events (TRAEs) were deemed serious; No DLTs reported in dose escalation, evaluated at oral doses of 40, 80, 160 and 320 mg QD.

IMM-1-104, a novel MEK inhibitor, blocks both MEK and ERK phosphorylation preventing CRAF bypass and hyperactivation of MEK. A short half-life of 2 hours combined with once daily dosing (QD) drives deep, pulsatile inhibition of the MAPK pathway at MEK in a process called Deep Cyclic Inhibition (DCI).

This study involves an experimental oral drug called IMM-1-104. The purpose of this study is to find out if IMM-1-104 is safe, can be tolerated in adults with advanced cancers, and whether IMM-1-104 will slow or stop cancers from growing.

Mar 22, 2024 · IMM-1-104, a once-daily oral treatment being evaluated in a Phase 1/2a trial for RAS-mutant solid tumors [NCT05585320], offers a novel deep cyclic inhibition (DCI) approach in targeting the MAPK pathway at MEK.

Sep 16, 2024 · IMM-1-104, a novel MEK inhibitor, blocks both MEK and ERK phosphorylation preventing CRAF bypass and hyperactivation of MEK. A short half-life of 2 hours combined with once daily dosing (QD) drives pulsatile inhibition of the MAPK pathway at MEK in a process called Deep Cyclic Inhibition (DCI).

IMM-1-104 is designed to provide universal-RAS activity through Deep Cyclic Inhibition of the MAPK pathway with once-daily oral dosing.

This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors.